María Victoria
Mateos Manteca
Profesora Titular de Universidad

Joaquín
Martínez López
2025
-
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
Blood Advances, Vol. 9, Núm. 3, pp. 571-582
-
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy
American Journal of Hematology, Vol. 100, Núm. 1, pp. 93-102
-
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
HemaSphere, Vol. 9, Núm. 4
-
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Journal of Clinical Oncology
-
Minimally Invasive Assessment of Peripheral Residual Disease during Maintenance or Observation in Transplant-Eligible Patients with Multiple Myeloma
Journal of Clinical Oncology, Vol. 43, Núm. 2, pp. 125-132
-
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment
Blood
2024
-
30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
HemaSphere
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715
-
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256
-
Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients
HemaSphere, Vol. 8, Núm. 12
-
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
HemaSphere, Vol. 8, Núm. 12
-
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
Annals of Hematology, Vol. 103, Núm. 12, pp. 5651-5661
-
Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma
Blood, Vol. 144, Núm. 23, pp. 2432-2438
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
-
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Haematologica, Vol. 109, Núm. 3, pp. 877-887
-
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
Haematologica, Vol. 109, Núm. 7, pp. 2219-2228
-
Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma
Clinical Cancer Research